Navigation Links
AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Date:3/5/2008

BENICIA, Calif., March 5 /PRNewswire/ -- AcroMetrix, a global leader in quality control materials and standards for molecular and serological diagnostics, announced today that it has entered into an agreement with Beckman Coulter Inc. for the development and supply of molecular quality control standards for various molecular targets.

AcroMetrix provides In Vitro Diagnostic manufacturers and clinical laboratories with quality control products for molecular testing of infectious disease, oncology, and genetics. These products provide a means by which to establish and monitor assay performance and estimate accuracy and detect systematic errors in molecular diagnostic assays.

"This agreement demonstrates the importance of quality control and standardization in molecular diagnostic testing. We are excited to be working with Beckman Coulter, a leader in the In Vitro Diagnostic industry," said Michael J. Eck, President and CEO for AcroMetrix.

The agreement includes the initial development and supply of quality control standards for 10 molecular targets that will be used in the development of Beckman Coulter's molecular UniCel DxN instrument. This agreement was made possible through AcroMetrix' Contract Manufacturing department which provides customers with high quality, tailored solutions enabling customers to benefit on the years of experience developed by AcroMetrix in the field of molecular quality control materials.

About AcroMetrix - AcroMetrix, with facilities in Benicia, California and Alkmaar, the Netherlands, provides a comprehensive line of molecular and serological diagnostic quality control products that assist laboratories in meeting current regulations regarding quality. AcroMetrix maintains this leadership role by consistently developing innovative standards, external run controls, and validation kits for molecular and serological testing in clinical diagnostics and blood screening laboratories. For more information on AcroMetrix please visit the company web site at http://www.acrometrix.com.


'/>"/>
SOURCE AcroMetrix
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Touch Bionics signs U.S. distribution agreement with SPS
2. Martek Signs Multi-Year Sole-Source Supply Agreement with Numico
3. The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions
4. Enigma Signs Real-Time PCR Licences With Applera
5. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
6. SemBioSys signs option agreement for safflower-produced food ingredient
7. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
8. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
9. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
10. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
11. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):